Date Filed | Type | Description |
01/08/2021 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
01/05/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
12/31/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
12/31/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
12/29/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/29/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/29/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/29/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/29/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/29/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/29/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/29/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/29/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/29/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
12/29/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
12/29/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
12/29/2020 |
RW
| Form RW - Registration Withdrawal Request: |
12/29/2020 |
RW
| Form RW - Registration Withdrawal Request: |
11/16/2020 |
8-K
| Other Events, Financial Statements and Exhibits |
08/17/2020 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
08/11/2020 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
08/03/2020 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
07/23/2020 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
07/13/2020 |
8-K
| Quarterly results |
07/07/2020 |
8-K
| Quarterly results |
06/19/2020 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
06/19/2020 |
8-K
| Quarterly results |
06/19/2020 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
06/08/2020 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
06/02/2020 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits |
05/08/2020 |
8-K
| Quarterly results |
05/06/2020 |
8-K
| Quarterly results |
05/06/2020 |
10-Q
| Quarterly Report for the period ended March 31, 2020 |
05/01/2020 |
8-K
| Entry into a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an...
Docs:
|
"Agreement Regarding Convertible Notes, by and among VIVUS, Inc., the Noteholder and the Trustee",
"VIVUS Announces Agreement with IEH Biopharma LLC Granting the Company a 30-Day Grace Period to Restructure its Corporate Debt CAMPBELL, CA., May 1, 2020 — VIVUS, Inc. , a biopharmaceutical company, today announced an agreement regarding its corporate debt with IEH Biopharma LLC, which holds a principal amount of approximately $170.1 million of the Company's Convertible Senior Notes with a maturity date of May 1, 2020. The Company does not currently have the ability to pay the principal amount of the Convertible Senior Notes held by IEH Biopharma. Under the terms of the agreement, the Company will pay IEH Biopharma $3.8 million in accrued and unpaid interest on the Convertible Senior Notes and IEH Biopharma will grant the Company a 30-day grace period , beginning today, for payment of the p..." |
|
|